XBI vs LABU ETF Comparison: AI Score, Valuation, Performance and Upside
XBI and LABU both track the S&P Biotechnology Select Industry Index, but for completely different investor types. XBI is a standard equity ETF suitable for long-term investors wanting diversified biotech exposure. LABU is a 3x daily leveraged ETF designed exclusively for short-term traders exploiting biotech momentum — its daily rebalancing creates volatility decay that makes it unsuitable for long-term holding. These are not equivalent alternatives.
XBI vs LABU is the standard equal-weight biotech ETF for long-term investors seeking diversified small-cap biotech exposure (XBI) versus the 3x daily leveraged biotech tactical trading vehicle for short-duration momentum plays on the same index (LABU) — core biotech holding vs short-term leveraged speculation tool.
XBI holds the edge across 3 of 5 key metrics in this comparison. LABU has delivered stronger 1-year price return (+268.40% vs +70.87% for XBI).
- →prefer long-term biotech sector exposure across 100+ companies with equal-weight methodology emphasizing small and mid-cap biotech growth potential
- →value XBI as a core biotech portfolio allocation for investors with 3–5+ year time horizons weathering FDA binary event volatility
- →want the most liquid and widely used biotech ETF for options hedging, sector rotation, and biotech benchmark comparison
- →are comfortable with high biotech sector volatility, binary FDA approval risk, and small-cap biotech funding environment sensitivity
- →need short-term tactical 3x leveraged exposure to biotech momentum — holding LABU for days or weeks around major FDA catalysts or biotech sector rallies
- →understand daily rebalancing volatility decay and actively manage holding periods to avoid long-term beta decay destruction
- →want leveraged biotech exposure without margin accounts or options complexity for tactical momentum trading
- →are comfortable with catastrophic downside risk (33% XBI decline = near-total LABU loss) and never intend to hold LABU as a core portfolio position
| Metric | XBI | LABU |
|---|---|---|
| ETF score | 61.0 | 22.0 |
| Latest close | $140.72 | $206.86 |
| 1M return | +10.99% | +31.89% |
| 6M return | +16.74% | +32.85% |
| 1Y return | +70.87% | +268.40% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | XBI | LABU |
|---|---|---|
| 1Y ago | $17.15K (+71.5%) started 2025-06-18 | $37.22K (+272.2%) started 2025-06-18 |
| 5Y ago | $10.65K (+6.5%) started 2021-06-18 | $1.52K (-84.8%) started 2021-06-18 |
| 10Y ago | $26.69K (+166.9%) started 2016-06-20 | $3.76K (-62.4%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
| Metric | XBI | LABU |
|---|---|---|
| Expense ratio | 0.35% | 0.96% |
| Total assets (AUM) | $8.39B | $571.29M |
| Dividend yield | 0.32% | 0.63% |
| Trailing P/E | N/A | N/A |
| Beta | 0.85 | 2.50 |
| 52-week change | 70.87% | 268.40% |
| Metric | XBI | LABU |
|---|---|---|
| 1Y return | +70.87% | +268.40% |
| 6M return | +16.74% | +32.85% |
| 1M return | +10.99% | +31.89% |
| 1Y Sharpe ratio | 2.01 | 2.01 |
| Beta | 0.85 | 2.50 |
| Dividend yield | 0.32% | 0.63% |
| 5Y CAGR | +1.16% | -31.63% |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | XBI | LABU |
|---|---|---|---|
| 1Y | Growth | +70.87% | +268.40% |
| CAGR | +70.93% | +268.73% | |
| Sharpe ratio | 2.01 | 2.01 | |
| Max drawdown | 9.72% | 30.70% | |
| Max daily drop | 4.39% | 12.94% | |
| Max wkly drop | 6.12% | 17.94% | |
| 5Y | Growth | +5.91% | -85.06% |
| CAGR | +1.16% | -31.63% | |
| Sharpe ratio | 0.06 | 0.04 | |
| Max drawdown | 54.71% | 97.59% | |
| Max daily drop | 8.21% | 24.52% | |
| Max wkly drop | 20.07% | 52.77% | |
| 10Y | Growth | +163.33% | -63.45% |
| CAGR | +10.17% | -9.58% | |
| Sharpe ratio | 0.32 | 0.33 | |
| Max drawdown | 63.89% | 98.96% | |
| Max daily drop | 12.35% | 33.37% | |
| Max wkly drop | 23.56% | 59.34% |
| Category | XBI | LABU |
|---|---|---|
| Fund name | State Street SPDR S&P Biotech ETF | Direxion Daily S&P Biotech Bull 3X Shares |
| Type | ETF | ETF |
| Expense ratio | 0.35% | 0.96% |
| Total assets (AUM) | $8.39B | $571.29M |
| Dividend yield | 0.32% | 0.63% |
- →Equal-weight methodology prevents large-cap dominance — XBI gives Regeneron and a small preclinical biotech similar weighting, maintaining exposure to high-upside early-stage biotechs
- →Broad 100+ company diversification reduces single-stock binary event risk compared to holding individual biotechs
- →High liquidity and options market depth make XBI the standard biotech hedging and speculation vehicle
- →3x daily leverage amplifies gains during biotech bull runs — LABU can generate extraordinary returns in short-duration biotech rallies
- →Provides leveraged biotech exposure without margin accounts or options — accessible to retail investors wanting biotech tactical exposure
- →Same index as XBI enables straightforward tracking of sector momentum with leveraged amplification
- →Equal-weight small/mid-cap biotech exposure creates higher drawdown risk than market-cap weighted biotech ETFs during biotech bear markets
- →Biotech is driven by binary FDA decisions — even diversified biotech ETFs can fall sharply when multiple high-profile drugs fail trials simultaneously
- →Biotech funding environments (interest rates, IPO market) heavily affect small biotech valuations and XBI price
- →Volatility decay (beta decay) causes LABU to lose value over time in volatile markets even if the index is flat — LABU is demonstrably not suitable for long-term holding
- →3x leverage amplifies losses equally: a 33% XBI decline wipes out LABU entirely — extreme downside risk during biotech drawdowns
- →LABU requires active monitoring and short holding periods — most retail investors who hold LABU too long experience significant underperformance vs 3x the XBI return due to daily rebalancing drag
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.